Answerth and Sons have been cutting hedges of all sizes for over 80 years and each one gets a little better.
Mar. 5—FAIRMONT — As the hospital once known as Fairmont Regional Medical Center closed last year, months later WVU Medicine stepped in to open Fairmont Medical Center. Cari Morgan, nursing director for the facility, which opened in mid-2020, said there was a void in health care in the community when the former facility closed. Now, WVU Medicine is filling that void. "Our main goal was to get ...
The George Floyd trial comes 30 years since another influential police brutality case.
Mar. 5—As vaccinations ramp up in Maine and nationwide, the Mills administration has announced changes to COVID-19 travel guidelines with an eye toward salvaging the 2021 summer tourism season. The changes mean that, beginning in May, most people from across the country can travel to Maine without having to first quarantine or get a COVID-19 test. The changes will directly affect Maine ...
Mar. 5—AUGUSTA — A partisan impasse over a budget bill could leave thousands of Maine businesses and unemployed workers paying state taxes on federal relief funds they received to help them weather the COVID-19 pandemic. The supplemental budget bill passed the Legislature's Appropriations and Financial Affairs Committee on an 8-5 party-line vote Thursday night, with Democrats in the majority ...
Mar. 5—Catholic churches in Maine will allow for 50 percent capacity at all Masses starting later this month, the Roman Catholic Diocese of Portland announced Friday. The announcement came shortly before Gov. Janet Mills unveiled a new plan loosening restrictions on indoor and outdoor gatherings and business activity. Starting March 26, the limit on all indoor gatherings increases to 50 ...
Mar. 5—The Oklahoma State Department of Health reported more than 900 new COVID-19 cases in the state Friday, including 22 in Norman. Friday's new case report brings Norman's cumulative case toll to 13,323. The state has reported 12,752 recoveries in Norman. Norman's death toll stands at 139. The state anticipates updating local death numbers each Tuesday, according to the health department. ...
Mar. 5—The University of Oklahoma's Board of Regents focused heavily on major steps in OU's strategic plan Friday, approving a consolidation plan for fundraising and the first steps of a massive housing replacement project. With the regents' unanimous vote Friday, OU's Office of University Advancement — responsible for fundraising operations — is moving under the existing OU Foundation, a ...
If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact:
A former Coral Gables police officer kicked off the force following accusations of domestic violence has lost his bid to win back his job.
Kill It With Fire is a first-person action game about hunting spiders and causing collateral damage.
Los Angeles, March 05, 2021 (GLOBE NEWSWIRE) -- The Chicago School of Professional Psychology (TCSPP) is pleased to announce that it has earned the 2021-2022 Military Friendly® School designation, with a gold standard of recognition. A Military Friendly® School designation recognizes The Chicago School’s commitment, effort and success in creating sustainable and meaningful benefit for the military community. Institutions earning the Military Friendly® School designation were evaluated using both public data sources and responses from a proprietary survey. More than 1,200 schools participated in the 2021-2022 survey with 750 earning the designation. The 2021-2022 Military Friendly® Schools list will be published in the May issue of G.I. Jobs magazine. “We are thrilled at this designation,” said TCSPP President, Michele Nealon, Psy.D. “We are driven by our gratitude for our military members, veterans and their families. Our commitment is to continue providing veterans and active military members with a supportive, affordable educational experience, and do all we can to support them in their transition from military to civilian life.” The Chicago School’s military initiatives include a partnership with National Military Family Association (NMFA) to offer potential scholarships exclusively to eligible NMFA military spouse members, and a veteran and active military tuition rate. Visit here for more information about The Chicago School of Professional Psychology’s student veteran and active military initiatives. Methodology, criteria, and weightings for Military Friendly® School designation were determined by Victory with input from the Military Friendly® Advisory Council of independent leaders in the higher education and military recruitment community. Final ratings were determined by combining the institution’s survey scores with the assessment of the institution’s ability to meet thresholds for Student Retention, Graduation, Job Placement, Loan Repayment, Persistence (Degree Advancement or Transfer) and Loan Default rates for all students and, specifically, for student veterans. About Military Friendly® Schools The Military Friendly® Schools list is created each year based on extensive research using public data sources for more than 8,800 schools nationwide, input from student veterans, and responses to the proprietary, data-driven Military Friendly® Schools survey from participating institutions. The survey questions, methodology, criteria and weighting were developed with the assistance of an independent research firm and an advisory council of educators and employers. The survey is administered for free and is open to all postsecondary schools that wish to participate. Criteria for consideration can be found at www.militaryfriendly.com. About The Chicago School of Professional Psychology Integrating theory with hands-on experience, The Chicago School of Professional Psychology provides education rooted in a commitment to innovation, service, and community for thousands of diverse students across the United States and globally. Founded in 1979, the nonprofit, regionally accredited university now features campuses in iconic locations across the country (Chicago, Southern California, Washington, D.C., New Orleans, Dallas) and online. To spark positive change in the world where it matters most, The Chicago School has continued to expand its educational offerings beyond the field of psychology to offer more than 20 degrees and certificates in the professional fields of health services, nursing, education, counseling, business, and more. Through its engaged professional model of education, commitment to diversity and inclusion, and an extensive network of domestic and international professional partnerships, The Chicago School’s students receive real-world training opportunities that reflect their future careers. The Chicago School is also a proud affiliate of TCS, a nonprofit system of colleges advancing student success and community impact. To learn more, visit www.thechicagoschool.edu. CONTACT: Lisa Riley The Chicago School of Professional Psychology (312) 646.9130 lriley@thechicagoschool.edu
First and only clinical T cell-based test for patients to detect the unique T-cell signature specific to SARS-CoV-2, the virus that causes COVID-19 T-Detect COVID correctly confirmed recent or prior COVID-19 infections 97.1% of the time from date of RT-PCR diagnosis with 100% specificity SEATTLE, March 05, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced that the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for T-Detect™ COVID to confirm recent or prior COVID-19 infection. This first-in-class T cell- based test is the first indication resulting from Adaptive’s TCR-Antigen Map collaboration with Microsoft (Nasdaq: MSFT). “We are proud to receive FDA Emergency Use Authorization for T-Detect COVID, the first indication in an entirely new class of tests that use T cells in the blood to detect disease. People who have been unsure about a prior infection will now have another way to know if they had the virus,” said Chad Robins, chief executive officer of Adaptive Biotechnologies. “The authorization of T-Detect COVID represents a true breakthrough for patients and a pivotal milestone for the diagnostic testing paradigm. We have proven that it is possible to read how T cells detect disease in the blood, and this is just the beginning of a pipeline of tests for many other indications.” EUA was based on a clinical validation study showing that T-Detect COVID demonstrated sensitivity of 97.1% from date of diagnosis using RT-PCR. Sensitivity is the ability of the test to correctly identify a positive case (true positive). T-Detect COVID also showed a specificity of 100%. Specificity is the ability of the test to identify a negative case (true negative). “This is the first commercially available T-cell test that confirms recent or prior SARS-CoV-2 infections in people. T-Detect is accurate and what I find especially remarkable is how rapidly it was developed. Going from the lab to real-world human impact in a matter of months demonstrates the true value of our collaboration and the power of merging biology with cloud-scale machine learning technology,” said Peter Lee, corporate vice president, Research & Incubations, Microsoft. “We are hopeful that this technology will have a meaningful impact not only in the global fight against COVID-19, but in many other disease areas in the future.” The FDA provides an EUA for medical products to be used in an emergency to diagnose, treat, or prevent serious or life-threatening diseases or conditions when there are no adequate, approved, and available alternatives. About the T cellT cells are the adaptive immune system’s first responders to detect any virus. They quickly multiply and circulate in the blood to attack the virus, often before symptoms appear. Among many other jobs, T cells also recruit B cells to produce antibodies after about a week or two to potentially provide immunity against future infection. T cells contain a treasure trove of information that could provide one consistent and trackable measure of the immune response to COVID-19 from initial exposure through viral clearance. T cells can “remember” prior infections and kill pathogens if they reappear. Research shows that antibodies to SARS-CoV-2 decline over time. T cells hold important clues to immunity and correlates of protection and need to be studied to assess how long patients remain resistant to reinfection. Given T cells circulate freely in the blood, they are an easy and thus a desirable target for assessing SARS-CoV-2 exposure and potentially immunity. About T-Detect™ T-Detect™ is a highly sensitive and specific diagnostic test under development for multiple diseases, translating the natural diagnostic capability of T cells into clinical practice. In 2018, Adaptive and Microsoft partnered to build a map of the immune system called the TCR-Antigen Map. This approach uses immunosequencing, proprietary computational modeling, and machine learning to map T-cell receptor sequences to disease-associated antigens for infectious diseases, autoimmune disorders and cancer. From a simple blood draw, T-Detect will leverage the map to provide an immunostatus for an individual, enabling early disease diagnosis, disease monitoring, and critical insights into immunity. T-Detect COVID is the first clinical test launched from this collaboration and the first commercially available T-cell test designed to detect recent or prior SARS-CoV-2 infections. T-Detect COVID is an EUA authorized test that is available for prescription use only. About Adaptive Biotechnologies Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed to develop products in life sciences research, clinical diagnostics and drug discovery. We have three commercial products and a robust clinical pipeline to diagnose, monitor and enable the treatment of diseases such as cancer, autoimmune conditions and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient. For more information, please visit adaptivebiotech.com and follow us on www.twitter.com/adaptivebiotech. Forward Looking Statements This press release contains forward-looking statements that are based on management’s beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations, including forward-looking statements contained in this press release or elsewhere related to T-Detect COVID and its ability to detect recent or prior COVID-19 infection, either in its current form or with respect to future mutations of the virus, as well as the potential application of T-Detect to additional disease states. In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law. MEDIA CONTACT:Beth Keshishian917-912-7195media@adaptivebiotech.com ADAPTIVE INVESTORS:Karina Calzadilla201-396-1687Carrie Mendivil, Gilmartin Groupinvestors@adaptivebiotech.com
Mar. 5—If you drive through Marietta and other parts of Cobb County, your license plate may be being watched. On public streets in Marietta and other parts of Cobb County, license plates are being read using technology that will tip off police if the plate is connected to a stolen car, or to a person with an outstanding arrest warrant. The Gateway Marietta Community Improvement District has ...
Sensient Technologies Corporation (NYSE: SXT) has announced the publication of its 2020 Sustainability Report. For the first time, the Company’s report aligns with topics and metrics from the Sustainability Accounting Standards Board (SASB) disclosure for the Chemicals industry, and begins to address the recommendations and supporting disclosures of the Financial Stability Board’s Task Force on Climate-related Financial Disclosures (TCFD).
If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact:
The final decision on the host cities for the 2026 World Cup is expected to be made in December.
Shareholder rights law firm Robbins LLP announces that a class action complaint has been filed on behalf of purchasers of Velodyne Lidar, Inc. securities (NASDAQ: VLDR, VLDRW). The complaint alleges that the Company and its officers and directors violated the Securities Exchange Act of 1934 between November 9, 2020 and February 19, 2021. Velodyne was founded by David Hall and provides solutions to develop safe automated systems including real-time surround view lidar sensors.
Dr. Francis Collins, director of the National Institutes of Health, is trying to get a pro-vaccine message out that centers on selflessness.
Buffalo Sabres coach Ralph Krueger’s status has been placed into question after first-year general manager Kevyn Adams called his underperforming team’s play “flat-out not good enough” during a wide-ranging conference call on Friday. Adams was short on specifics when it came to Krueger, saying “everything is under evaluation” and adding he has full authority from owners Terry and Kim Pegula to make hockey decisions. “He understands the situation we’re in is unacceptable, and the players do, everybody does,” Adams said of the second-year coach.
Hand gestures are commonplace in the Senate, but Sen. Kyrsten Sinema is getting flack for the way she voted against a $15 minimum wage.
Yahoo Home